S&P 500   3,328.80 (+0.24%)
DOW   29,218.62 (+0.08%)
QQQ   224.64 (+0.61%)
AAPL   318.42 (+0.58%)
MSFT   166.42 (-0.05%)
GOOGL   1,488.82 (+0.44%)
AMZN   1,891.91 (+0.00%)
CGC   24.58 (+1.78%)
BABA   223.18 (+0.41%)
MU   59.66 (+1.17%)
GE   11.42 (-2.06%)
TSLA   588.37 (+7.52%)
AMD   51.67 (+1.21%)
T   39.07 (+1.43%)
ACB   2.04 (+1.49%)
NFLX   331.86 (-1.85%)
PRI   126.86 (+0.36%)
BAC   34.25 (-0.03%)
DIS   143.99 (+0.30%)
GILD   63.11 (+0.77%)
S&P 500   3,328.80 (+0.24%)
DOW   29,218.62 (+0.08%)
QQQ   224.64 (+0.61%)
AAPL   318.42 (+0.58%)
MSFT   166.42 (-0.05%)
GOOGL   1,488.82 (+0.44%)
AMZN   1,891.91 (+0.00%)
CGC   24.58 (+1.78%)
BABA   223.18 (+0.41%)
MU   59.66 (+1.17%)
GE   11.42 (-2.06%)
TSLA   588.37 (+7.52%)
AMD   51.67 (+1.21%)
T   39.07 (+1.43%)
ACB   2.04 (+1.49%)
NFLX   331.86 (-1.85%)
PRI   126.86 (+0.36%)
BAC   34.25 (-0.03%)
DIS   143.99 (+0.30%)
GILD   63.11 (+0.77%)
S&P 500   3,328.80 (+0.24%)
DOW   29,218.62 (+0.08%)
QQQ   224.64 (+0.61%)
AAPL   318.42 (+0.58%)
MSFT   166.42 (-0.05%)
GOOGL   1,488.82 (+0.44%)
AMZN   1,891.91 (+0.00%)
CGC   24.58 (+1.78%)
BABA   223.18 (+0.41%)
MU   59.66 (+1.17%)
GE   11.42 (-2.06%)
TSLA   588.37 (+7.52%)
AMD   51.67 (+1.21%)
T   39.07 (+1.43%)
ACB   2.04 (+1.49%)
NFLX   331.86 (-1.85%)
PRI   126.86 (+0.36%)
BAC   34.25 (-0.03%)
DIS   143.99 (+0.30%)
GILD   63.11 (+0.77%)
S&P 500   3,328.80 (+0.24%)
DOW   29,218.62 (+0.08%)
QQQ   224.64 (+0.61%)
AAPL   318.42 (+0.58%)
MSFT   166.42 (-0.05%)
GOOGL   1,488.82 (+0.44%)
AMZN   1,891.91 (+0.00%)
CGC   24.58 (+1.78%)
BABA   223.18 (+0.41%)
MU   59.66 (+1.17%)
GE   11.42 (-2.06%)
TSLA   588.37 (+7.52%)
AMD   51.67 (+1.21%)
T   39.07 (+1.43%)
ACB   2.04 (+1.49%)
NFLX   331.86 (-1.85%)
PRI   126.86 (+0.36%)
BAC   34.25 (-0.03%)
DIS   143.99 (+0.30%)
GILD   63.11 (+0.77%)
Log in
(Ad)
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NASDAQ:MAXY - Maxygen Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company's interests in Perseid Therapeutics LLC, the Company's former subsidiary, which included all of the Company's research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company's wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:MAXY
CUSIP57777610
Phone+1-650-2412292

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MAXY News and Ratings via Email

Sign-up to receive the latest news and ratings for MAXY and its competitors with MarketBeat's FREE daily newsletter.


Maxygen (NASDAQ:MAXY) Frequently Asked Questions

What is Maxygen's stock symbol?

Maxygen trades on the NASDAQ under the ticker symbol "MAXY."

Has Maxygen been receiving favorable news coverage?

Media stories about MAXY stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Maxygen earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Maxygen.

Who are some of Maxygen's key competitors?

What is Maxygen's official website?

The official website for Maxygen is http://www.maxygen.com/.

How can I contact Maxygen?

Maxygen's mailing address is 725 San Aleso Ave Ste 2, SUNNYVALE, CA 94085-1400, United States. The biotechnology company can be reached via phone at +1-650-2412292.


MarketBeat Community Rating for Maxygen (NASDAQ MAXY)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  79
MarketBeat's community ratings are surveys of what our community members think about Maxygen and other stocks. Vote "Outperform" if you believe MAXY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAXY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel